News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Week In Review: Vivace Details Its Capital Efficient Plan To Develop Novel Cancer Therapies



7/31/2017 9:34:30 AM

  Life Sciences Jobs  
  • Newest Jobs - Last 24 Hours
  • California Jobs
  • Massachusetts Jobs
  • New Jersey Jobs
  • Maryland Jobs
  • Washington Jobs
  View More Jobs
Company Spotlight
- In an exclusive interview, Sofie Qiao, PhD, President/CEO of Vivace Therapeutics, discussed the novel science behind Vivace's portfolio and the company's US-China capital-efficient business plan;
Deals and Financings
- Seattle's Rodeo Therapeutics announced a $5.9 million financing, including participation by WuXi AppTec, for small-molecule therapies to promote tissue repair;
- Nanjing Frontier Biotechnologies acquired global rights to a novel broad-spectrum HIV neutralizing antibody from Rockefeller University of the US;
Industry Insights
- We list and profile the top 10 China pharma companies ranked by a combination of each company's revenues and market capitalization;
Trials and Approvals
- The CFDA approved a superficial radiation therapy device made by Sensus Healthcare of the US to treat and prevent keloids;
- DelMar Pharma, a Canada-US biopharma, was approved to start a China Phase II trial of its lead candidate, which targets glioblastoma multiforme.

Read at ChinaBio Today


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES